AUTHORS
Rui Ji, PhD, Xiaoli Liang2, Xianjing Cheng3, Rui Yin4, Weixuan Zhang5, Longfei Yang6, Xinwen Zhang7, Yibo Wang8, Lichao Liu9, Meng Yuan10, Yidan Ye11, Renrui Liu12, Ruihao Huang13, Changzheng Li14, Xiaoqi Wang, MD, PhD15, Xi Zhang, MD16
AFFILIATIONS
1 Xinqiao Hospital Army Medical University, Chongqing, China
2 Xinqiao Hospital Army Medical University, Chongqing, China
3 Xinqiao Hospital Army Medical University, Chongqing, China
4 Xinqiao Hospital Army Medical University, Chongqing, China
5 Xinqiao Hospital Army Medical University, Chongqing, China
6 Xinqiao Hospital Army Medical University, Chongqing, China
7 Xinqiao Hospital Army Medical University, Chongqing, China
8 Xinqiao Hospital Army Medical University, Chongqing, China
9 Xinqiao Hospital Army Medical University, Chongqing, China
10 Xinqiao Hospital Army Medical University, Chongqing, China
11 Xinqiao Hospital Army Medical University, Chongqing, China
12 Xinqiao Hospital Army Medical University, Chongqing, China
13 Xinqiao Hospital Army Medical University, Chongqing, China
14 The Fifth Affiliated Hospital, Guangzhou Medical University, Guangdong, China
15 Xinqiao Hospital Army Medical University, Chongqing, China
16 Xinqiao Hospital Army Medical University, Chongqing, China
ABSTRACT
Background:
Previous studies have shown that, following allogeneic haematopoietic stem cell transplantation, each organ independently establishes a distinct immune microenvironment. Nevertheless, systemic immunity is not a mere aggregate of independent organ-specific compartments; rather, cross-organ immunoregulatory mechanisms interconnect these tissues. The present study therefore aimed to elucidate organ-specific immune reconstitution and cross-organ immune communication after allo-HSCT.
Methods:
We retrospectively analyzed 243 patients who developed GVHD after allo-HSCT to define patterns of organ involvement and predictors of disease dissemination. In murine GVHD models, we performed single-cell RNA sequencing (scRNA-seq) and used Kaede photoconvertible donor mice to trace immune-cell migration in vivo. ScRNA-seq and spatial transcriptomics of patient skin biopsies were used to define the cellular and molecular niches associated with disseminating T cells. The therapeutic potential of IL-17 blockade was evaluated in preclinical models and a pilot clinical study.
Results:
To investigate differences and interconnections in immune reconstitution across organs after allo-HSCT, we selected GVHD, the most important organ-specific immune event during immune reconstitution, as our analytical target. In a retrospective analysis of 243 patients who developed GVHD after allo-HSCT, we identified 2 principal organ-distribution patterns: skin-dominant and liver-dominant. Skin GVHD was frequently accompanied by oral GVHD (OR, 3.9) and ocular GVHD (OR, 3.8), whereas liver GVHD was associated with joint GVHD (OR, 5.1) and lung GVHD (OR, 2.6). Logistic regression further showed that skin GVHD at initial diagnosis predicted subsequent de novo GVHD in other organs (OR, 3.9; 95% CI, 1.84–7.99; P < .01) in a dose-dependent manner, whereas GVHD in other organs showed no such effect, indicating that skin GVHD is intrinsically disseminating.
ScRNA-seq of murine tissues revealed marked transcriptional similarity between immune cells in GVHD-affected skin and eye. Following local photoconversion of donor-derived immune cells in the skin of mice receiving Kaede-expressing grafts, Kaede-red cells were substantially enriched in the cornea compared with other organs (36.4% vs 5.3%) and were predominantly IL-17+ T cells. Cell-cell communication analysis indicated that corneal cells recruited these cells through the CXCL16-CXCR6 axis. CXCL16 neutralization ameliorated GVHD and reduced ocular accumulation of skin-derived IL-17+ T cells.
To investigate how the cutaneous GVHD microenvironment generates IL-17+CXCR6+ T cells, we analyzed scRNA sequencing of skin biopsy from cGVHD patients. Subclustering of immune cells revealed a distinct T-cell population coexpressing IL17A and CXCR6. SCENIC analysis additionally revealed increased FOS activity in T cells from murine skin and eye and in patient skin. To characterize the cutaneous GVHD immune microenvironment, we profiled skin biopsies by spatial RNA sequencing and mapped molecular and cellular niches . This approach demonstrated significant spatial colocalization of IL-17+CXCR6+ T cells with ACKR1+ inflammatory endothelial cells, which exhibited markedly enhanced antigen-presenting capacity. These endothelial cells may recruit IL-17+CXCR6+ T cells into the systemic circulation through dermal venules, thereby promoting dissemination of cutaneous GVHD to distant organs. Spatial molecular-niche analysis revealed that serine-sphingolipid metabolism characterized the immune microenvironment of the IL-17+CXCR6+ T-cell and ACKR1+ inflammatory endothelial-cell niche.
Finally, we evaluated the translational potential of IL-17 blockade as a source-intervention strategy for cGVHD. In preclinical models, administration of secukinumab, a neutralizing anti–IL-17 antibody, was effective and safe in alleviating cGVHD, with no overt treatment-related toxicity. Building on these findings, we conducted a pilot clinical study in patients with cGVHD.
Conclusions:
Skin GVHD can act as a source of systemic disease by generating IL-17+CXCR6+ central-memory T cells that migrate to distant organs, particularly the eye, through the CXCL16-CXCR6 axis. ACKR1+ inflammatory endothelial cells and a distinct metabolic niche in the skin may sustain and mobilize this pathogenic population. Targeting IL-17 with secukinumab may interrupt cGVHD dissemination at its source and represents a promising therapeutic strategy for multisystem cGVHD.
DISCLOSURES
Xi Zhang, MD: No relevant conflicts of interest to declare.